France’s Ipsen SA is delivering on one of its strategic aims, to build up its early clinical R&D pipeline in a small number of targeted therapeutic areas including neuroscience, by licensing exclusive worldwide rights to IRLAB Therapeutics AB’s clinical-stage candidate, mesdopetam, for use in Parkinson’s disease.
Mesdopetam (IRL-790) appears to be in the sweet-spot of Paris-headquartered Ipsen, being a novel, oral, dopamine D3-receptor antagonist which has completed Phase IIa studies and